A Clinical Trial of Enlicitide and Rosuvastatin in Healthy Adults (MK-0616-039)
A Clinical Study to Evaluate the Relative Bioavailability of FDC Tablets Containing Enlicitide and Rosuvastatin, Compared to Enlicitide and Rosuvastatin Administered Concomitantly as Single Entities, in Healthy Adult Participants
Merck Sharp & Dohme LLC
60 participants
Dec 29, 2025
INTERVENTIONAL
Conditions
Summary
This goal of this trial is to learn about two medicines, enlicitide and rosuvastatin, in healthy people. Researchers will compare the amounts of enlicitide and rosuvastatin in a person's body over time, when they are given as separate medicines and when they are combined into one tablet.
Eligibility
Inclusion Criteria2
- Is medically healthy with no clinically significant medical history
- Is a non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to study entry
Exclusion Criteria2
- Is unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications, herbal remedies, or vitamin supplements beginning 14 days prior to study entry
- Is a female participant of childbearing potential
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Enlicitide/rosuvastatin fixed dose combination (FDC) or enlicitide/rosuvastatin FDC formulation B oral tablets
Oral tablet
Oral tablet
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07300280